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MicroRNA‑494‑3p inhibits 
formation of fast oxidative muscle 
fibres by targeting E1A‑binding 
protein p300 in human‑induced 
pluripotent stem cells
Hirotaka Iwasaki1, Yoshinori Ichihara2, Katsutaro Morino3*, Mengistu Lemecha3,5, 
Lucia Sugawara3, Tatsuya Sawano2, Junichiro Miake2, Hidetoshi Sakurai4, Eiichiro Nishi1, 
Hiroshi Maegawa3 & Takeshi Imamura2
MYOD‑induced microRNA‑494‑3p expression inhibits fast oxidative myotube formation by 
downregulating myosin heavy chain 2 (MYH2) in human induced pluripotent stem cells (hiPSCs) during 
skeletal myogenesis. However, the molecular mechanisms regulating MYH2 expression via miR‑
494‑3p remain unknown. Here, using bioinformatic analyses, we show that miR‑494‑3p potentially 
targets the transcript of the E1A‑binding protein p300 at its 3′‑untranslated region (UTR). Myogenesis 
in hiPSCs with the Tet/ON‑myogenic differentiation 1 (MYOD1) gene (MyoD‑hiPSCs) was induced 
by culturing them in doxycycline‑supplemented differentiation medium for 7 days. p300 protein 
expression decreased after transient induction of miR‑494‑3p during myogenesis. miR‑494‑3p mimics 
decreased the levels of p300 and its downstream targets MYOD and MYH2 and myotube formation 
efficiency. p300 knockdown decreased myotube formation efficiency, MYH2 expression, and basal 
oxygen consumption rate. The binding of miR‑494‑3p to the wild type p300 3′‑UTR, but not the 
mutated site, was confirmed using luciferase assay. Overexpression of p300 rescued the miR‑494‑3p 
mimic‑induced phenotype in MyoD‑hiPSCs. Moreover, miR‑494‑3p mimic reduced the levels of p300, 
MYOD, and MYH2 in skeletal muscles in mice. Thus, miR‑494‑3p might modulate MYH2 expression 
and fast oxidative myotube formation by directly regulating p300 levels during skeletal myogenesis in 
MyoD‑hiPSCs and murine skeletal muscle tissues.
The skeletal muscle comprises muscle fibres with different patterns of gene expression, which lead to differences 
in contractile dynamics and metabolic properties. In humans, muscle fibres are classified into three types based 
on different myosin heavy chain (MYH) isoforms. These isoforms determine muscle-fibre function during devel-
opment and  adulthood1. MYH7 is a marker for type I slow-twitch oxidative myofibres, MYH2 is a marker for 
type IIa fast-twitch oxidative myofibres, and MYH1 is a marker for type IIx fast-twitch glycolytic  myofibres2,3. 
Myofibre composition correlates with pathophysiology of certain disorders such as  diabetes4,  sarcopenia5,6, and 
muscular  disease7,8. Differentiation of skeletal muscle is driven by basic helix-loop-helix transcription factors 
called muscle regulatory factors (MRFs) and MYOD is one of the well-characterised MRFs. MYOD can induce 
the differentiation of fibroblasts into  myotubes9 and can bind to histone acetyltransferases (HATs) including 
 p30010. Genetic studies in embryonic stem (ES) cells have shown that intrinsic HAT activity of p300 is specifically 
required for skeletal myogenesis and MYOD gene  expression11. p300-dependent hyperacetylation also regulates 
muscle  wasting12.
MicroRNAs (miRNAs) are small non-coding RNA molecules, typically 19- to 24-bp, that are processed 
by Dicer to generate their mature  form13. miRNAs suppress multiple genes by destabilisation or reduction of 
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 translation14. Myogenic processes are also regulated by  miRNAs15,16. Muscle-specific miRNAs such as miR-1, 
-133, -206, -208, -208b, -486, and -499 have been demonstrated to participate in physiological and patho-
logical skeletal muscle processes such as myogenesis, regeneration, hypertrophy, and muscular  dystrophy17–23. 
Among them, miR-1, -206, and -486 are induced by MYOD expression and their expression is increased during 
 myogenesis24,25. Moreover, miR-208b and miR-499 control fibre type and muscle  performance21. Recent studies 
also support the involvement of non-muscle-specific miRNAs in  myogenesis26–29. We found that among these 
non-muscle-specific miRNAs, the expression of miR-494-3p was transiently induced by MYOD induction and 
reduced during  myogenesis30. Previous studies showed that miR-494-3p expression was decreased by endur-
ance exercise in mouse skeletal  muscles31,32. We have also reported that miR-494-3p expression represses type 
IIa fast-twitch oxidative muscle fibre differentiation in a skeletal myogenesis model, using human iPS cells 
stably expressing the Tet/ON-MYOD1 gene (MyoD-hiPSCs)30. Since miR-494-3p showed unique expression 
patterns and was regulated by exercise, we focused on miR-494-3p in this study. miR-494-3p regulates multiple 
genes such as PTEN33, SIRT134, c-Myc34, PDE4D35, cyclinD136, Rab5a37, PAK138, IGF1R39, Tfam31, Foxj331, and 
Pgc1α40. Although overexpression of miR-494-3p in MyoD-hiPSCs decreased the protein expression of MYH2, 
the underlying mechanism remains unclear, as no recognition site of miR-494-3p in the 3′-UTR of the MYH2 
gene has been found.
Based on our previous findings, we hypothesised that target proteins of miR-494-3p may be involved in the 
machinery regulating fibre type-specific skeletal myogenesis. Thus, in this study, we aimed to identify the direct 
target of miR-494-3p during fibre-type-specific skeletal myogenesis.
Results
MiR‑494‑3p downregulated protein expression of p300 during human‑skeletal myogenesis in 
MyoD‑hiPSCs. We first searched for potential direct targets of miR-494-3p, which regulate fibre-specific 
skeletal myogenesis, using miRNA target prediction software. miR-494-3p expression in MyoD-hiPSCs was 
transiently upregulated 24 h after myogenic induction and was reduced to basal levels at day 5, and further 
decrease was observed until day7 (Fig. 1a). This result indicates that potential target proteins of miR-494-3p 
may be decreased after myogenic induction. Thus, we tested the expression patterns of some potential target 
proteins during MyoD-hiPSC differentiation. We found three candidates p300, SIRT1, and PTEN, whose protein 
expression decreased on days 3 and 7 compared with that on day 1 (Fig. 1b,c). To examine whether this reduced 
expression depends on miR-494-3p, we transfected a miR-494-3p mimic into MyoD-hiPSCs on day 1 to increase 
miR-494-3p levels during skeletal myogenesis (Fig. 1d). Increased expression of miR-494 was observed one day 
after transfection (day 2), which continued to increase up to 3000-fold on day 7 compared with that before trans-
fection; the extent of increase was then reduced compared with that on day 2 or 3 (Fig. 1e). p300 expression was 
significantly reduced on day 7 by exogenous expression of miR-494-3p (p < 0.001), whereas the levels of SIRT1 
and PTEN were not changed, compared with the levels in the control (Fig. 1f,g). We also found that p300 mRNA 
expression was unchanged on days 3 and 7 compared with that on day 0 during MyoD-hiPSC differentiation 
(Supplementary Fig. S1). Since p300 is a coactivator of MYOD, we analysed the expression of MYOD and MYH2 
as downstream molecules of p300 in skeletal myogenesis to clarify the mechanism of action of miR-494-3p in 
myogenesis. The expression of MYOD was significantly downregulated by miR-494 overexpression compared 
with that in the control on day 3 (p < 0.05) (Fig. 1h,i). The expression of MYH2 was downregulated by miR-494 
overexpression compared with that in the control on day 7 (Fig. 1h). These results suggest that p300 is a possible 
downstream regulator of miR-494-3p in the regulation of MYOD expression during human skeletal myogenesis.
Effects of miR‑494 inhibitor on skeletal myogenesis in MyoD‑hiPSCs. Next, we performed miR-
494-3p inhibitor treatments to confirm the contribution of the transient increase in miR-494-3p expression to 
skeletal myogenesis on day 1 in hiPSCs. MyoD-hiPSCs were transfected with miR-494-3p inhibitor on day 0 
before myogenic induction (Supplementary Fig. S2a). The expression of the MYH2 protein was decreased in 
cells transfected with the miR-494-3p mimic, whereas it was unchanged in cells transfected with the miR-494-3p 
inhibitor compared with that in the control (Supplementary Fig. S2b,c). There was no difference in the number 
of differentiated myotubes and myotube size between cells transfected with the miR-494-3p inhibitor and the 
control (Supplementary Fig. S2d–f).
Effects of p300 knockdown on human‑skeletal myogenesis in MyoD‑hiPSCs. To confirm the 
contribution of p300 to skeletal myogenesis in hiPSCs, we performed siRNA-induced knockdown of p300. 
MyoD-hiPSCs were transfected with specific siRNAs against p300 (si-p300) on days 1 and 4 after myogenic 
induction (Fig. 2a). Compared with that in control, si-p300 reduced p300 protein expression to approximately 
50% on days 4 and 7 (Fig. 2b,c). This result shows that the protein expression of p300 was consistently reduced 
from day 4 to 7 during skeletal myogenesis. The ratio of myotube formation, assessed as the number of cells 
in myotubes to that of total cells, showed a 60% decrease regarding cells with si-p300 compared with the con-
trol. Moreover, compared with that in control, si-p300 reduced the length of myotubes to approximately 50% 
(Fig. 2d–f). This reduction followed the results of miR-494-3p overexpression (Fig. 2d–f). Myotube formation 
was also evaluated by fusion index, showing a 60% decrease in cells treated with si-p300 compared with myotube 
formation in the control, which was similar to that in cells treated with miR-494 mimic (Supplementary Fig. S3). 
Western blotting revealed that the level of MYH2, a specific marker for type IIa myofibres, was reduced by both 
si-p300 and the miR-494-3p mimic (Fig. 2g,h). The levels of MYH7, a specific marker for type I myofibres, and 
MYH1, a specific marker for type IIx myofibres, were unaffected by si-p300 or miR-494-3p mimic (Fig. 2g). The 
myogenin (MYOG) level was unchanged for both si-p300 and miR-494 mimic treatments (Fig. 2i). miR-494 
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expression was also unaffected by si-p300 on day7 (Fig. 2j). These results suggest that p300 is a possible down-
stream target of miR-494-3p during skeletal myogenesis in hiPSCs.
Metabolic effects of p300 knockdown on skeletal myogenesis in MyoD‑hiPSCs. We used 
NADH-TR staining to examine the oxidative activity of cells treated with si-p300 because miR-494-3p over-
expression inhibits the formation of fast oxidative type IIa  myotubes30. Compared with that in control, p300 
knockdown decreased the ratio of NADH-positive cells to total cells in myotubes by 40% (Fig. 3a,b). We then 
Figure 1.  Effects of miR-494 mimic on human-skeletal myogenesis in MyoD-hiPSCs. (a) Time course of miR-
494 expression during MyoD-hiPSC differentiation, as analysed by Taqman RT-qPCR. Data were normalised 
with snRNA U6. n = 4–6. *p < 0.05. (b,c) Time course of p300, SIRT1, and PTEN expression during MyoD-
hiPSC differentiation, as analysed by immunoblotting. Expression of p300, SIRT1, and PTEN was quantified 
using Image J and normalised to β-actin expression. n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 versus day 0. 
#p < 0.05, ###p < 0.001 versus day 1. Full-length blots are presented in Supplementary Figure S4. (d) Schematic 
diagram showing transfection of MyoD-hiPSCs with miR-494 mimic at day 1. (e) Time course of miR-494 
expression during differentiation of MyoD-hiPSCs transfected with miR-494 mimic, as analysed by Taqman 
RT-qPCR. Data were normalised with snRNA U6. n = 3. ***p < 0.001 versus day 0. ###p < 0.001 versus day 1. (f,g) 
MyoD-hiPSCs were transfected with miR-494 mimic or negative control duplexes (Control). Whole-cell extracts 
were harvested at day 7 after myogenic induction; expression of p300, SIRT1 and PTEN was evaluated using 
immunoblots. Data were normalised to β-actin. n = 6. ***p < 0.001 versus control. Full-length blots are presented 
in Supplementary Figure S5. (h) Time course of p300, MYOD, and MYH2 expression during differentiation of 
MyoD-hiPSCs transfected with miR-494 mimic or Control, as analysed by immunoblotting. Full-length blots 
are presented in Supplementary Figure S6. (i) MyoD-hiPSCs transfected with miR-494 mimic or Control were 
harvested at day 3 after myogenic induction; expression of p300 and MYOD was evaluated using immunoblots. 
Data were normalised to β-actin. n = 5. *p < 0.05 versus control.
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examined the myotube metabolism of MyoD-hiPSCs by evaluating their oxygen consumption rate using a flux 
analyser. Compared with that in the control, basal respiration in cells with si-p300 decreased by 50% on day 7 
after myogenic induction (Fig. 3c,d). The maximal respiratory capacity of cells with si-p300 was decreased by 
Figure 2.  Effects of p300 knockdown on human-skeletal myogenesis in MyoD-hiPSCs. (a) Schematic diagram 
showing transfection of MyoD-hiPSCs with siRNA against p300 (si-p300) at days 1 and 4. (b,c) MyoD-hiPSCs 
were transfected with si-p300 or negative control duplexes (Control). Whole-cell extracts were harvested at day 
4 and 7 after myogenic induction, and p300 expression was evaluated using immunoblotting. p300 expression 
was quantified using Image J and normalised to β-actin. n = 5. *p < 0.05, ***p < 0.001 versus control. Full-length 
blots are presented in Supplementary Figure S8. (d) Representative images of MyoD-hiPSCs at day 7 post-
transfection with Control, si-p300, and miR-494 mimic. Scale bars: 100 µm. (e,f) The number (e) and length (f) 
of differentiated myotubes at day 7 was analysed in each microscopic field. n = 10 (e), n = 7 (f). ***p < 0.001 versus 
control. (g) Expression of myosin heavy chain 2 (MYH2), MYH7, and MYH1 in MyoD-hiPSCs transfected with 
Control, si-p300, or miR-494 mimic at day 7 after myogenic induction, as assessed via western blotting. Full-
length blots are presented in Supplementary Figure S9. (h) The level of MYH2 was quantified using Image J and 
normalised to β-actin. n = 5. *p < 0.05, **p < 0.01 versus control. (i) Expression of myogenin (MYOG) in MyoD-
hiPSCs transfected with Control, si-p300, or miR-494 mimic at day 7 after myogenic induction, as assessed 
via western blotting. Full-length blots are presented in Supplementary Figure S10. (j) miR-494 expression in 
MyoD-hiPSCs transfected with Control and si-p300 at day 7 after myogenic induction, as analysed by Taqman 
RT-qPCR. Data were normalised with snRNA U6. n = 3.
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70% compared with the control (Fig. 3c,f). Proton leakage and non-mitochondrial respiration were unchanged 
(Fig. 3c,e,g). These results indicate that mitochondrial content in the muscle cells treated with si-p300 decreased, 
leading to a weaker oxidative phenotype. p300 expression was essential for both formation and metabolism of 
highly oxidative myotubes. This follows the results of miR-494-3p overexpression shown in our previous  study30. 
Namely, miR-494-3p overexpression reduces the formation of fast oxidative myotube by inhibiting p300 expres-
sion. MYH2 is a marker for a fast oxidative fibre containing more mitochondria.
Overexpression of p300 rescued the effects of miR‑494 in human‑skeletal myogenesis. To 
clarify the role of p300 as a downstream target of miR-494-3p during skeletal myogenesis from hiPSCs, res-
cue experiments were performed using MyoD-hiPSCs transfected with both miR-494 mimic and p300 expres-
sion vector. We performed co-transfection with the miR-494 mimic and p300 expression vector on day 1 from 
myogenic induction and analysed the expression levels of MYOD and MYH2 on day 7 (Fig.  4a). Decreased 
expression of p300 induced by miR-494 overexpression was recovered by co-overexpression of p300 on day 7 
(Fig. 4b,c). Decreased expression of MYOD and MYH2, induced by miR-494 mimic, was also rescued by co-
overexpression of p300 (Fig. 4b,c). These results indicate that overexpression of p300 at least partially abolished 
the effects of miR-494-3p on MyoD-hiPSCs during human-skeletal myogenesis.
Cells transfected with a miR-494-3p mimic and a blank vector showed a decrease in the number of dif-
ferentiated myotubes to 70% of control cells on day 7 (Fig. 4d,e). Co-overexpression of p300 and miR-494-3p 
mimic restored the percentage of differentiated myotubes to 90% compared with the control (Fig. 4d,e). Moreo-
ver, compared with the control, the miR-494-3p mimic and a blank vector reduced the length of myotubes to 
approximately 50% (Fig. 4d,f). Co-overexpression of p300 and miR-494-3p mimic restored the percentage of the 
length of myotubes to 95% compared with the control (Fig. 4d,f). Flux analyser showed that cells transfected with 
miR-494-3p mimic and a blank vector exhibited a decrease of 40% in basal respiration and maximal respiratory 
Figure 3.  Metabolic effects of p300 knockdown on human-skeletal myogenesis in MyoD-hiPSCs. (a) 
NADH-TR staining detected myotube fibre types in MyoD-hiPSCs transfected with si-p300 or Control at day 
7 after myogenic induction. Representative images are presented. Scale bars: 100 µm. (b) The graph shows the 
ratio of the number of stain-positive myotubes to total cell number counted in each microscopic field (n = 10). 
*p < 0.05 versus control. (c) MyoD-hiPSCs transfected with si-p300 or Control were evaluated using flux 
analyser at day 7 after myogenic induction. Levels of basal oxygen-consumption rate (OCR) were measured, 
and mitochondrial stress tests were performed using oligomycin (Oligo), FCCP, and rotenone-antimycin A. A 
representative example of five independent experiments is shown. (d–g) After the OCR measurements, cells 
were lysed, and protein concentration was measured to normalise OCR data obtained for basal respiration (d), 
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capacity compared with the control on day 7 (Fig. 4g,h,j). Proton leakage and non-mitochondrial respiration, 
however, were unchanged (Fig. 4g,i,k). Co-overexpression of p300 and miR-494-3p mimic restored the rate 
of basal respiration and maximal respiratory capacity to 90% compared with the control (Fig. 4g,h,j). These 
data show that miR-494-3p inhibited the formation of fast-twitch oxidative fibres, and this effect was rescued 
by overexpression of p300 in MyoD-hiPSCs, which suggest the inhibitory effect of miR-494-3p on fast-twitch 
oxidative fibre formation via p300.
p300 is a potential target of miR‑494‑3p. Next, we explored the target of miR-494-3p in MyoD-hiPSCs. 
The microRNA.org prediction software identified p300 as one of the potential candidate targets of miR-494-3p. 
The expression of p300 was decreased in response to overexpression of miR-494-3p (Fig. 1f,g). The sequences 
of miR-494-3p were compared with the 3′-UTR of p300, and thereby a binding sequence for miR-494-3p was 
conserved between human and mice (Fig. 5a). We next performed a luciferase reporter assay using a construct 
containing the 3′-UTR region of p300 inserted downstream of the luciferase-coding sequence. The relative lucif-
erase activity of the wild-type p300 3′-UTR was significantly reduced when miR-494-3p mimics were transfected 
(Fig. 5b). In contrast, overexpression of miR-494-3p did not affect the expression of the luciferase reporter with 
the p300 3′-UTR containing mutations in the putative miR-494-3p-binding sequence (Fig. 5c). These data sug-
gest a direct binding between miR-494-3p and the 3′-UTR sequence of p300.
Local administration of miR‑494‑3p mimic inhibited p300, MYOD, and MYH2 protein expres‑
sion in mouse skeletal muscle. We finally tested whether local overexpression of miR-494-3p could 
downregulate p300 expression in mice. A miR-494-3p mimic was injected in the TA muscle of one leg, and 
negative control mimic was injected in the contralateral leg as previously  described41–43. miR-494-3p levels were 
significantly increased at about 3-times in the skeletal muscle transfected with miR-494-3p mimic (p < 0.01) 
(Fig. 6a). Injection of miR-494-3p in the TA muscle inhibited protein levels of p300 and its downstream targets, 
MYOD and MYH2 (Fig. 6b,c). MYH1, MYH4, MYH7, and MYOG levels were unchanged in the TA muscle 
treated with miR-494 mimic (Fig. 6b,c). We also examined the protein expression levels of the mitochondrial 
biogenesis regulators, transcription factor A, mitochondrial (TFAM), cytochrome c oxidase I (MTCO1), and 
mitochondrial and succinate dehydrogenase complex, subunit A (SDHA). As expected, the protein levels of 
them showed significant downregulation in miR-494-3p mimic-injected samples (Fig. 6d,e). These results dem-
onstrate that miR-494-3p mediates the formation of fast oxidative type IIa myotubes in vivo.
Discussion
In this study, we showed that the miR-494-p300-MYH2 axis regulates fast oxidative skeletal myogenesis in MyoD-
hiPSCs and showed its physiological relevance in mouse muscle tissue. This study has revealed two important 
findings. First, the overexpression of miR-494-3p reduced p300 protein levels followed by the downregulation 
of MYOD and MYH2 protein expression, and attenuated the formation of fast oxidative type IIa myotubes and 
oxygen consumption in the differentiation of MyoD-hiPSCs. Second, the miR-494-3p mimic reduced the levels 
of p300 protein and its downstream targets, MYOD and MYH2, in mouse skeletal muscle. These findings dem-
onstrate that miR-494-3p directly inhibits the expression of p300 and formation of type IIa fast-twitch oxidative 
myofibres in vitro and in vivo.
We showed that miR-494-3p reduced the protein expression of p300 and attenuated the formation of highly 
oxidative type IIa myotubes and oxygen consumption in skeletal myogenesis in MyoD-hiPSCs. We used com-
putational miRNA target prediction algorithms and identified p300 as one of the target genes for miR-494-3p. 
We confirmed the miR-494-3p-binding site in the 3′-UTR of p300 (Fig. 5b,c), a transcriptional coregulator. This 
binding sequence is evolutionally conserved in mammals, including human and mouse. Previously, we showed 
that overexpression of miR-494-3p in MyoD-hiPSCs inhibits protein expression of MYH2 and formation of type 
IIa-like  myotubes30. In this study, we found that p300 expression was reduced during myogenesis and was further 
reduced by the expression of miR-494-3p mimic (Fig. 1h,i). We confirmed that siRNA-induced knockdown of 
Figure 4.  Effects of p300 overexpression on human-skeletal myogenesis in MyoD-hiPSCs transfected with 
miR-494 mimic. (a) Schematic of co-transfection of MyoD-hiPSCs with miR-494 and p300 construct. (b) 
MyoD-hiPSCs were transfected with scrambled control and blank vector (Control), miR-494 mimic and blank 
vector (miR-494 mimic) or miR-494 mimic and p300 expression vector (miR-494 mimic + p300). Whole-cell 
extracts were harvested at day 7 after myogenic induction; expression of p300 and MYH2 was analysed using 
immunoblots. Full-length blots are presented in Supplementary Figure S11. (c) p300 expression was quantified 
using Image J and normalised to β-actin. n = 5. *p < 0.05. (d) Representative cell images show MyoD-hiPSCs at 
day 7 after transfection with Control, miR-494 mimic, or miR-494 mimic + p300. Scale bars: 100 µm. (e,f) The 
number (e) and length (f) of myotubes differentiated at day 7 was counted in each microscopic field (n = 4). 
Data are expressed as the ratio of experimental values to control values. n = 3. *p < 0.05, ***p < 0.001. (g) MyoD-
hiPSCs transfected with Control, miR-494 mimic, or miR-494 mimic + p300 at day 7 after myogenic induction 
were evaluated by a flux analyser. We then measured basal oxygen-consumption rate (OCR) and performed a 
mitochondrial stress test using oligomycin, FCCP, and rotenone-antimycin A. A representative example of three 
independent experiments is shown. Data are expressed as the mean ± SE of five wells. Bonferroni correction was 
performed to evaluate the association between the groups: *p < 0.05 miR-494 mimic versus control. **p < 0.01 
miR-494 + p300 versus miR-494 mimic. (h,k) After the OCR measurements, cells were lysed, and protein 
concentration was measured to normalise the OCR data obtained for basal respiration (h), proton leakage (i), 
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p300 inhibited MYH2 expression and reduced the rate of oxygen consumption and formation of mitochondria-
rich myotubes (Figs. 2, 3), consistent with the effects of miR-494 overexpression. Overexpression of p300 rescued 
the effects of transfection with a miR-494-3p mimic (Fig. 4). These results indicate that p300 is a direct target of 
miR-494-3p during the formation of fast oxidative type IIa-like myotubes from human iPS cells. However, many 
direct target genes of miR-494-3p other than p300 may exist, and targets of miR-494-3p may vary in each organ 
or cell type. A recent study in rats showed that treatment with ethanol upregulates the levels of p300 by reduc-
ing the expression of miR-494 in the amygdaloid  nucleus44. In mouse beige adipocytes, miR-494-3p regulates 
mitochondrial biogenesis and thermogenesis via PGC1-α  signalling40. In mouse skeletal muscle, miR-494-3p 
regulates mitochondrial biogenesis via Tfam and Forkhead box  j331. Other studies have shown that miR-494-3p 
is an oncogene and plays a central role in developing many types of solid tumours. miR-494-3p promotes hyper-
activation of the PI3K/AKT pathway and progression of human hepatocellular carcinoma by targeting  PTEN33.
As shown in Fig. 1h,i, MYOD expression was also reduced after myogenic induction during myogenesis 
and was further reduced by treatment with the miR-494-3p mimic on day 3. The reduction in MYOD expres-
sion could lead to many effects of the miR-494 mimic. It is important to know how miR-494 inhibits MYOD 
expression in the MyoD-hiPSCs system. We assume that miR-494 down regulates MYOD expression indirectly. 
MYOD has a positive feedback loop to stimulate its own expression. Decreased expression of p300 by miR-494-3p 
resulted in decreased expression of MYOD. Thus, these results suggest that the MYOD/miR-494/p300 axis is 
a novel pathway in regulating human skeletal myogenesis and composition of myofibres because p300 plays a 
role in MYOD  activation45. As shown in Fig. 4, co-overexpression of p300 restored the expression of MYOD and 
MYH2, which had been reduced by the miR-494-3p mimic. Based on these results, we suggested a novel mecha-
nism for regulating MYOD after myogenic induction. p300 regulates cell function by mediating the activity of 
HATs and by interacting with different transcription factors and  coactivators46–50. p300 activates myogenic regula-
tion and elongation factors, promoting myogenesis via its downstream effectors, MYOD and myogenic factor 5 
(MYF5)46. Studies have shown that p300 is critical for induction of MYOD and for determination of myogenic cell 
fate in vivo51. In Tet on MyoD-hiPSCs system, exogenous MYOD was induced during Tet treatment, but protein 
expression of MYOD was downregulated after myogenic induction during myogenesis (Fig. 1h,i). In this study, 
MYOD transiently induced the expression of miR-494-3p, which downregulates p300 protein expression. p300 
expression in hiPS cells was high in basal and decreased by MYOD after myogenic induction. These results sug-
gest that p300 protein expression in hiPS cells was decreased by miR-494-3p induced by MYOD after myogenic 
induction. So, we assume that MYOD induced miR-494-3p has a novel negative feedback loop which decreases 
MYOD expression itself and downregulates downstream of MYOD regulated genes. On the other hand, p300 
knockdown did not change the miR-494 expression on day 7 (Fig. 2j). Therefore, we believe p300 does not affect 
the expression of miR-494-3p, at least in our experimental condition.
This study has some debatable issues. First is the difference between MyoD-hiPSCs and human primary myo-
tubes. The largest difference between the two cell types lies in the expression of MYF5 and MYH2. A previous 
report showed that MyoD-hiPSCs showed high similarity with primary myotubes except for MYF5  expression52. 
Moreover, another report has shown that primary myotubes express sarcomere isoforms such as MYH3, MYH7, 
MYH8, and MYH13, but not adult fast skeletal muscle isoforms (MYH1, MYH2, and MYH4)53. This discrepancy 
could be a strength of MyoD-hiPSCs.
The second issue is the time lag between p300 and miR-494 expression. As shown in Fig. 1a, miR-494-3p 
expression increased from day 0 to day 1 and then decreased. However, the protein expression of p300 was stable 
on days 0 and 1 and decreased only on day 3 (Fig. 1b). It is unclear how these endogenous levels are directly 
correlated. We speculate that the increase in miR-494 expression on day 1 inhibited p300 with some time lag. 
Previous reports have shown similar time lags between miRNA-induced inhibition of translation and the target 
protein  content54–57. The half-life of p300 is reported to be approximately 11–14 h in several cells  lines58–61. We 
Figure 5.  p300 mRNA is a target of miR-494-3p. (a) The multiple alignments of hsa-miR-494-3p sequence, and 
3′-UTR of p300 mRNA from human and mice. The seed region of miRNA and putative target sequences in p300 
genes are shown in capital letters. (b,c) Luciferase reporter assays. Luciferase reporters containing the p300 wild-
type (b) or mutant 3′-UTR (c) were transfected along with miR-494-3p mimic or scrambled sequence control 
into MyoD-hiPSCs at day 2 after myogenic induction and analysed 2 days later. n = 5. ***p < 0.001 versus control.
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also found that p300 mRNA expression was unchanged on day 3 compared with that on day 0 during MyoD-
hiPSC differentiation (Supplementary Fig. S1). This result suggests post-transcriptional regulation of p300 during 
MyoD-hiPSC differentiation.
Third, the MYH2 protein expression and the number of differentiated myotubes were unchanged in cells 
transfected on day 0 with miR-494-3p inhibitor (Supplementary Fig. S2). The reason underlying these results 
remains unknown. In our previous study, experiments conducted with miR-494 inhibitor showed there was no 
difference in the number of differentiated myotubes and oxygen consumption between cells transfected with 
the miR-494 inhibitor and those transfected with the scrambled control on day  730. These results suggest that 
the efficacy of miR-494 inhibitor may be too weak. Alternatively, there might be a mechanism compensating for 
the effects of miR-494 knockdown, potentially by upregulating other miRNAs.
Human skeletal muscle fibre composition is affected by diseases such as type 2 diabetes and sarcopenia. Thus, 
the fourth issue is how miR-494-3p expression is affected by type 2 diabetes and sarcopenia. To date, no study 
has shown the significance of miR-494 in the skeletal muscle in type 2 diabetes and sarcopenia. However, a pre-
vious study showed that miR-494 expression was upregulated by tumour necrosis factor-α and desensitised the 
insulin effect in C2C12 muscle  cells62. In another study, miR-494-3p expression induced by compressive force 
Figure 6.  Effects of miR-494-3p mimic in TA muscle in mice. (a) miR-494 expression was measured by 
Taqman RT-qPCR in TA muscle of C57BL/6J mice injected with miRNA control mimic (Control) or miR-
494-3p mimic (miR-494 mimic). Data were normalised with snRNA U6. n = 3. **p < 0.01. (b) p300, MYOD, 
MYH2, MYH1, MYH4, MYH7, and MYOG protein levels were measured by immunoblots in TA muscle of 
C57BL/6J mice injected with miRNA control mimic (Control) or miR-494-3p mimic (miR-494 mimic). Full-
length blots are presented in Supplementary Figure S12. (c) The intensity of western blot bands was quantified 
by Image J and was normalised to β-actin. n = 6. *p < 0.05 versus control. (d) TFAM, MTCO1, and SDHA 
protein levels were measured by immunoblots in TA muscle of C57BL/6J mice injected with Control or miR-494 
mimic. Full-length blots are presented in Supplementary Figure S13. (e) The intensity of western blot bands was 
quantified by Image J and was normalised to β-actin. n = 6. *p < 0.05 versus control.
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inhibited proliferation in MC3T3-E1  cells63. Furthermore, miR-494-3p has been linked to insulin-resistance 
and type 2  diabetes64,65.
We found that the miR-494-3p mimic reduced the levels of p300 protein and its downstream targets, MYOD 
and MYH2, in murine skeletal muscle. Moreover, the levels of key mitochondrial biogenesis regulators, such 
as TFAM, MTCO1, and SDHA protein levels, was also reduced with miR-494-3p mimic injection in TA. Our 
results suggest that miR-494-3p mediates fast oxidative myotube formation and mitochondrial biogenesis in vivo. 
These findings corroborate those in our previous report, in which acute exercise reduced the expression of 
miR-494-3p in skeletal muscle in  mice31. Other reports also showed reduced miR-494-3p expression in muscles 
after  exercise32,66. The mechanisms of muscle fibre type conversion against exercise may be partially medi-
ated by miR-494-3p, like the mechanism we observed in this study. To confirm the impact of miR-494-3p on 
muscle fibre type conversion against exercise, further investigations are necessary. To examine the function of 
miR-494-3p more clearly in skeletal muscles, we have initiated the construction of miR-494 flox mice using the 
CRISPR-Cas9 system. Further experiments in miR-494 knockout mice may help elucidate the role of miR-494 
in skeletal muscle in vivo.
In summary, our findings proved that miR-494-3p inhibited the formation of fast oxidative myotube by 
directly targeting p300 in skeletal myogenesis in human iPS cells and probably in vivo as well.
Methods
Materials. The primary antibodies used in this study were as follows: Mouse anti-MYOD (sc-377460), anti-
myosin heavy chain 7 (MYH7; sc-53089), anti-β-actin (sc-47778), monoclonal antibodies (mAbs), rabbit anti-
p300 (sc-584), anti-SIRT1 (H-300), and anti-MYH2 (sc-53095) polyclonal antibodies (pAbs) were purchased 
from Santa Cruz Biotechnology (Dallas, TX, USA). Rabbit anti-MYH1 (25182-1-AP) and anti-MYH4 (20140-
1-AP) pAb were purchased from Proteintech (Rosemont, IL, USA). Rabbit anti-PTEN (#9559) mAb was pur-
chased from Cell Signalling Technology (Danvers, MA, USA). Mouse anti-SDHA (ab14715), rabbit anti-TFAM 
(ab131607) pAb, and mouse anti-MTCO1 (ab14705) mAb were purchased from Abcam (Cambridge, UK). 
Mouse anti-MYOG (556358) mAb was purchased from BD Pharmingen (San Diego, CA, USA). Mouse anti-
human myosin heavy chain mAb was purchased from R&D systems (Minneapolis, MN, USA). Goat anti-mouse 
IgG-HRP (sc-2005) and goat anti-rabbit IgG-HRP (sc-2004) secondary antibodies were purchased from Santa 
Cruz Biotechnology (Dallas, TX, USA). All other reagents were purchased from Wako Chemicals (Kyoto, Japan).
In‑silico analysis. To analyse the target sequences of miR-494-3p, we used computational target predic-
tion programmes (microRNA.org67 and  TargetScanHuman68). We screened the target genes of miR-494-3p with 
evidence for target interaction, as predicted by microRNA.org (mirSVR score < − 0.5) and TargetScanHuman 
(cumulative weighted context++ score < − 0.2). We used these thresholds to obtain a high-confidence list of 
candidate targets of miR-494-3p. Next, we selected genes controlling fibre type-specific skeletal myogenesis via a 
literature search using the MeSH terms “Fibre-type”, “Skeletal muscle”, and “skeletal myogenesis”.
Mice. This study was approved by the Animal Care and Use Committee of the Shiga University of Medical 
Science (Otsu, Japan). All animal experiments were carried out in accordance with the Guidelines for the Hus-
bandry and Management of Laboratory Animals of the Research Center for Animal Life Science at Shiga Univer-
sity of Medical Science. Male C57BL/6J mice (8-week-old) were obtained from Charles River Japan (Yokohama, 
Japan) and maintained on a chow diet with ad libitum access to water. Mice were maintained in environmentally 
controlled rooms.
In vivo transfection of miRNA mimic. Injection of miR-494-3p mimics into the TA muscles of C57BL/6J 
mice was performed according to manufacturer’s instruction with minor modifications. In brief, fifty microliters 
of 250 μM miR-494-3p mimic (MC12409, Thermo Fisher Scientific, Waltham, MA, USA) were mixed with 333 
μL of Invivofectamine 2.0 reagent (Thermo Fisher Scientific, Waltham, MA, USA) and the mixture incubated for 
30 min at room temperature. As a control, fifty microliters of 250 μM negative control (4464059, Thermo Fisher 
Scientific, Waltham, MA, USA) were used. 15 mL of 5% glucose was added to the mixture and concentrated 
using Amicon Ultracel-100 (Merck, Darmstadt, Germany) to 300 μL. Finally, 50 μL of miRNA complex (2.5 mg/
kg) was injected into the TA muscle of one leg, and the negative control complex was injected into the contralat-
eral leg. These procedure were repeated for 6 days and sacrificed at day 7 of injecting to harvest muscle samples.
Human‑skeletal myogenesis in MyoD‑hiPS cell line. The model of human-skeletal myogenesis was 
established as described  previously52. Briefly, human iPS cells [clone: 201B7, provided by CiRA (Kyoto Uni-
versity, Japan)] were stably transfected with a PB-TAC-ERN vector encoding myogenic differentiation 1 gene 
(Tet/ON-MYOD1)-IRES-mCherry cDNA. Then, the appropriate cell clones (MyoD-hiPSCs) were chosen via 
G418 selection. For myogenic differentiation, MyoD-hiPSCs were seeded onto Matrigel (BD Biosciences, San 
Jose, CA, USA) or Synthemax II-SC Substrate (Corning, Corning, NY, USA)-coated dishes without feeder cells. 
Twenty-four hours after seeding (day 0), doxycycline (1 mg/mL) was added to the ES cell medium. Twenty-
four hours after induction via doxycycline (day 1), culture medium was replaced with differentiation medium 
composed of alpha Minimal Essential Medium (aMEM; Nacalai Tesque, Kyoto, Japan) supplemented with 5% 
Knockout Serum Replacement (KSR; Thermo Fisher Scientific, Waltham, MA, USA) and doxycycline (1 mg/
mL), as described  previously52. Two MyoD-hiPSCs clones (#2 and #11) were used to confirm reproducibility in 
most experiments performed in this study.
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Cell culture and transfection. MyoD-hiPSCs were cultured and maintained on inactive SNL feeder cells 
(DS Pharma Biomedical, Osaka, Japan), as described  previously52, in primate ES cell medium (Nacalai Tesque, 
Kyoto, Japan) supplemented with recombinant human basic fibroblast growth factor at a concentration of 4 ng/
mL (Wako Chemicals, Wako, Japan).
MyoD-hiPSCs were transfected with miR-494-3p mimic (MC12409, Thermo Fisher Scientific, Waltham, MA, 
USA), miR-494-3p inhibitor (MH12409, Thermo Fisher Scientific, Waltham, MA, USA), or scrambled control 
(AM17110, Thermo Fisher Scientific, Waltham, MA, USA) using lipofection reagent RNAiMAX (Thermo Fisher 
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. For overexpression of miR-494-3p, 
MyoD-hiPSCs were transfected with 5 nM of miR-494-3p mimic on day 1 after induction with doxycycline, and 
assayed on day 7 or on the day following myogenic induction. For knockdown of miR-494-3p, MyoD-hiPSCs 
were transfected with 5 nM of miR-494-3p inhibitor on day 0 after induction with doxycycline and assayed on 
day 7 after myogenic induction.
To knock down p300, MyoD-hiPSCs were transfected with 10 nM of a specific siRNA on days 1 and 4 after 
myogenic induction, using RNAiMAX (Thermo Fisher Scientific, Waltham, MA, USA) and then assayed on day 
7. Reproducibility of all results was confirmed using two siRNAs against p300 (s4696 and s4697; Thermo Fisher 
Scientific, Waltham, MA, USA).
For overexpression of p300 using a 1245 pCMVb p300 expression vector (Addgene, Cambridge, MA, USA), 
MyoD-hiPS cells were co-transfected with 5 nM of miR-494 mimic and 30 nM of p300 construct on day 1 after 
myogenic induction using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, USA), and then assayed 
on day 7. Control cells were transfected with scrambled control and pCMVb blank vector using the same protocol 
as described above.
Luciferase reporter assay. Luciferase reporter assay was performed as previously  described31. In brief, 
dual reporter expression clones of human wild-type p300 3′-UTR in pEZX-MT06 vector were obtained from 
Genecopoeia (Rockville, MD, USA). The mutant p300 3′-UTR reporter was created by mutating the seed regions 
of the predicted hsa-miR-494-3p site (from UUG UGG UUU CUG UUUC to UUG UGG UUU CUC AAAG). The 
3′-UTR sequences were inserted downstream of a firefly luciferase reporter gene driven by an SV40 enhancer. 
The Renilla luciferase reporter was an internal control for transfection efficiency. The plasmids were transfected 
into human iPS cells on day 2 after myogenic induction, using polyethyleneimine (PEI) “Max” (Polysciences, 
Warrington, PA, USA) according to the manufacturer’s instructions. Dual luciferase activity was measured using 
the Dual-Glo Luciferase Assay System (Promega, Madison, WA, USA) according to the manufacturer’s instruc-
tions on day 4.
Nucleic acid and protein quantification. Total RNA and cellular protein were isolated using a miRvana 
PARIS kit (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer’s instructions. Protein 
expression was examined via western blotting as described  previously52. cDNA was prepared using Prime-
Script 2 first-strand cDNA synthesis kit (Takara Bio, Otsu, Japan). RT-qPCR was preformed using SYBR Green 
PCR master mix (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer’s instructions. All 
quantitative data were normalised against expression levels of β-actin. miR-494-3p expression was analysed by 
RT-qPCR using a TaqMan miRNA assay kit (002365; Thermo Fisher Scientific, Waltham, MA, USA), accord-
ing to the manufacturer’s instructions. U6 small RNA was used as the internal control for miR quantification 
(001973; Thermo Fisher Scientific, Waltham, MA, USA). Primer sets used in this study are listed in Supplemen-
tary Table S1.
Analysis of cellular metabolism. Metabolic activity in skeletal myotubes was measured as cellular 
oxygen consumption via XF-24 flux analyser (Seahorse Bioscience, North Billerica, MA, USA), as described 
 previously30. Cells were seeded at a density of 50,000 cells per well and cultured overnight in full growth medium. 
After overnight attachment, the medium was washed and replaced with XF assay medium. Levels of basal OCR 
were measured, followed by a mitochondrial stress test. Each value was corrected regarding protein concentra-
tion, and all measurements were repeated at least three times.
Live cell staining. Live cell staining was performed as previously  described30. In brief, for nicotinamide 
adenine dinucleotide-tetrazolium reductase (NADH-TR) staining, cells were incubated with NADH-TR solu-
tion (56 mM Tris-base; 0.16 M Tris–HCl, pH 7.4; 1.2 mM Nitro blue tetrazolium; and 1.0 mM NADH) for 
30 min at 37 °C and then washed with phosphate buffered saline. Images were captured using a BZ-9000 (Key-
ence, Osaka, Japan) and the positive cells were counted manually. Over three images per dish were counted, and 
the average values were used to calculate the positive cell ratio in the experiment. We have shown the means of 
10 independent experiments in graphs.
Assessment of myotube length. Myotube length was determined on day 7. Images were captured using 
a BZ-9000 (Keyence, Osaka, Japan). The myotube length was determined by measuring the average length of 
long multinucleate fibres using the Image J software. For estimating the mean value of myotube length, the five 
largest myotubes in five fields for each of the three wells per sample were measured.
Quantitative analysis of the fusion index. The fusion index was analysed as described  previously69. On 
day 7 after inducing differentiation, myotubes were immunostained with anti-myosin heavy chain and DAPI. 
Images were captured using a BZ-9000 (Keyence, Osaka, Japan) and the fusion index was calculated as the ratio 
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of the nuclei number in myotubes (cells having over two nuclei) to the total nuclei number from five random 
fields for each experiment. We show the means of four independent experiments in graphs.
Statistical analysis. All data were expressed as mean ± SEM. We performed statistical analysis by using 
GraphPad Prism7 software (San Diego, CA, USA). The significance of differences between two groups were 
evaluated by Student’s t-test. One-way ANOVA and Bonferroni’s multiple comparisons test were used to deter-
mine differences between the multiple groups. p < 0.05 was considered significant.
Conference Presentation. A part of the current study was presented at the 18th World Congress of Basic 
and Clinical Pharmacology in Kyoto, Japan from July 1st to 6th, 2018.
Data availability
No datasets were generated or analysed during the current study.
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